Latest Articles
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - MSN
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial MSN
Published: June 21, 2026, 4:52 a.m.
Where to buy the iPhone 17 Pro: Best carrier deals and outright prices - Mashable
Where to buy the iPhone 17 Pro: Best carrier deals and outright prices Mashable
Published: June 20, 2026, 10:20 p.m.
Dostarlimab Provides Long-Term Benefits in dMMR/MSI-H Endometrial Cancer - OncLive
Dostarlimab Provides Long-Term Benefits in dMMR/MSI-H Endometrial Cancer OncLive
Published: June 20, 2026, 1:04 p.m.
Miscarriage Risk During Early Pregnancy Linked to Bending Over Frequently, Standing and Walking at Work, in New Study - AOL.com
Miscarriage Risk During Early Pregnancy Linked to Bending Over Frequently, Standing and Walking at Work, in New Study AOL.com
Published: June 20, 2026, 9:08 a.m.
Free NHS prescriptions could be widened to three conditions and two million people - Birmingham Live
Free NHS prescriptions could be widened to three conditions and two million people Birmingham Live
Published: June 20, 2026, 8 a.m.
Former Dublin LGFA star Hannah Tyrrell opens up about pregnancy after health diagnosis - MSN
Former Dublin LGFA star Hannah Tyrrell opens up about pregnancy after health diagnosis MSN
Published: June 20, 2026, 8 a.m.
Amazon just knocked 35% off the Kindle Scribe Premium Pen - Mashable
Amazon just knocked 35% off the Kindle Scribe Premium Pen Mashable
Published: June 20, 2026, 3:04 a.m.
Validation of Endometriosis Fertility Index for the Prediction of Non-Assisted Reproductive Technology (ART) Pregnancy in Women With Endometriosis-Associated Infertility: A Prospective Cohort Study - Cureus
Validation of Endometriosis Fertility Index for the Prediction of Non-Assisted Reproductive Technology (ART) Pregnancy in Women With Endometriosis-Associated Infertility: A Prospective Cohort Study Cureus
Published: June 19, 2026, 10:11 p.m.
Nivolumab Produces 68% Clinical CR Rate in Resectable dMMR Endometrial Cancer - OncLive
Nivolumab Produces 68% Clinical CR Rate in Resectable dMMR Endometrial Cancer OncLive
Published: June 19, 2026, 5:49 p.m.
Puxitatug Samrotecan Hits 60% Response Rate in Platinum- and IO-Pretreated Endometrial Cancer - Targeted Oncology
Puxitatug Samrotecan Hits 60% Response Rate in Platinum- and IO-Pretreated Endometrial Cancer Targeted Oncology
Published: June 19, 2026, 5:05 p.m.
Link copied to clipboard!